Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet

Journal:

Journal of Clinical Investigation

Published:

2025-07-01

DOI:

10.1172/jci184422

Affiliations:

8

Authors:

17

Go to article

Institutions	Authors	Share
Centre Georges-François Leclerc (CGFL), France	4.800000	0.28
University of Burgundy Europe, France	4.066667	0.24
Lipids, Nutrition, Cancer (LNC), France	4.066667	0.24
Genomic and Immunotherapy Medical Institute (GIMI), France	3.233333	0.19
Biomedical Imaging Laboratory (LIB), France	0.333333	0.02
Dijon University Hospital, France	0.250000	0.01
Imagine Institute, France	0.250000	0.01

Interested in Oncology and Carcinogenesis?